Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, lung adenocarcinoma, lung disorder, lung neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, non-small cell squamous lung carcinoma, respiratory system disorder, respiratory tract neoplasm, urinary system disorder | Active, not recruiting | Phase 1 | 2026-09-30 | NCT05873686 | |
| Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | non-small cell lung carcinoma | Recruiting | Phase 1 | 2026-08-25 | NCT07784959 | |
| Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-07-09 | NCT07315113 |